Coveo Relevance Generative Answering
Coveo Introduces Two New Groundbreaking GenAI Business Applications and 15+ AI Innovations in the New Coveo Spring Release
March 28, 2024 09:00 ET | Coveo Solutions Inc.
Innovations to Coveo’s Industry-Leading Enterprise AI Platform facilitate deployment of multi-channel enterprise-grade generative answering that delivers b
Logo.png
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
March 28, 2024 08:00 ET | Cocrystal Pharma, Inc.
FDA feedback following the Company’s submission of a Pre-IND briefing package improves clarity on regulatory requirements for Phase 2b influenza A clinical trial with oral CC-42344, a broad-spectrum...
Acrivon logo.jpg
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
March 28, 2024 08:00 ET | Acrivon Therapeutics, Inc
WATERTOWN, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision...
2023-03-27_Fig.1
Dore Copper Identifies Gold Exploration Potential at Norhart Zone, Just North of the Former Joe Mann Mine
March 27, 2024 17:30 ET | DORÉ COPPER MINING CORP
TORONTO, March 27, 2024 (GLOBE NEWSWIRE) -- Doré Copper Mining Corp. (the "Company" or "Doré Copper") (TSXV: DCMC; OTCQX: DRCMF; FRA: DCM) reports that it has completed its first review of the...
gaia.jpg
Gaia Reports Fourth Quarter and Full Year 2023 Results
March 27, 2024 16:05 ET | Gaia, Inc.
BOULDER, Colo., March 27, 2024 (GLOBE NEWSWIRE) -- Gaia, Inc. (NASDAQ: GAIA) (“Gaia” or the “Company”), a conscious media and community company, reported financial results for the fourth quarter and...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients
March 26, 2024 06:30 ET | Praxis Precision Medicines, Inc.
In the 45 mg cohort, 100% of patients achieved a complete response In the 15 mg cohort, 80% of patients achieved a complete response and 20% achieved a partial response Safety was consistent with...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines to Host PRAX-628 Program Update
March 25, 2024 16:01 ET | Praxis Precision Medicines, Inc.
Presentation will be held virtually on Tuesday, March 26, 2024 at 8:00 a.m. ET Praxis leadership will be joined by key opinion leader in epilepsy Dr. Daniel Friedman, Professor of Neurology at...
Absci-NameLogo.png
Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results
March 21, 2024 07:30 ET | Absci Corporation
Initiated IND-enabling studies for ABS-101, a potential best-in-class anti-TL1A antibody Entered into collaboration with AstraZeneca for up to $247M in deal value, plus royalties Strengthened...
image2.png
Eisbach and Cancer Focus Fund Announce $4.5 Million Investment to Support First-in-Human Phase 1/2 Trial of EIS-12656 for Refractory Advanced Solid Tumors
March 21, 2024 07:00 ET | Cancer Focus Fund; Eisbach Bio GmbH
Cancer Focus Fund is investing $4.5M for clinical trial of Eisbach's novel approach using synthetic lethality to kill PARP inhibitor resistant tumors
US FDA approves Idor
US FDA approves Idorsia’s once-daily TRYVIO (aprocitentan) – the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives
March 20, 2024 02:00 ET | Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR TRYVIO™ (aprocitentan) is indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult...